Previous 10 | Next 10 |
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase ...
Lumos Pharma (NASDAQ: LUMO) , a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (“PGHD”) through phase 2 clinical trials, has received a notice of allowance for a submitted patent. The notice was received from the U.S. P...
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that on Thursday, March 14, 2024, the Company recei...
2024-03-07 17:45:08 ET Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Conference March 07, 2024 04:30 PM ET Company Participants Lisa Miller - Vice President, IR Rick Hawkins - CEO and Chairman John McKew - President and CSO Duke Pitukcheewanont - CMO Lori La...
2024-03-07 16:32:56 ET More on Lumos Pharma Lumos Pharma, Inc. 2023 Q3 - Results - Earnings Call Presentation Lumos Pharma promotes Pisit Pitukcheewanont to chief medical officer Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for...
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Pisit “Duke” ...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...
2024-03-06 17:35:33 ET Major earnings expected after the bell on Thursday include: Costco Wholesale Corporation ( COST ) Broadcom ( AVGO ) DocuSign ( DOCU ) Marvell Technology ( MRVL ) Petróleo Brasileiro ( PBR ) Read the full article o...
2024-03-06 17:20:06 ET More on Lumos Pharma Lumos Pharma, Inc. 2023 Q3 - Results - Earnings Call Presentation Lumos Pharma promotes Pisit Pitukcheewanont to chief medical officer Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for...
News, Short Squeeze, Breakout and More Instantly...
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the...
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted f...
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months ...